Allergen Aesthetics, an AbbVie company, announced in the Journal of Cosmetic Dermatology the published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase 3 clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX® Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment.
The peer-reviewed study found that, 30 days after receiving treatment, 90.5% of all study patients reported being either mostly or very satisfied with receiving a natural look, as rated on a five-point scale.
This satisfaction was sustained by more than 80% of patients throughout the 12-month study period for the temporary improvement in the appearance of their moderate to severe UFLs.
In addition, 30 days after receiving treatment, more than half of treated patients reported an improvement in self- perceived appearance and psychological wellbeing, defined as those who achieved a meaningful improvement in five areas (how much their facial lines made them feel older, feel unhappy, look angry, look tired, or feel that they negatively affected self-esteem). UFLs, which include forehead, glabellar, and crow’s feet lines, fall within the
main areas of concern for individuals considering aesthetic treatments.1 The study, titled Self-Perception of Natural Outcome, Appearance and Emotional Well-Being After OnabotulinumtoxinA Treatment for Upper Facial Lines: Post- Hoc Analysis Across Age and Gender, analysed patient-reported outcomes (PROs) from more than 450 neurotoxin- naïve adults treated who saw a reduction in UFL severity with onabotulinumtoxinA (BOTOX® Cosmetic). The study used the Facial Line Satisfaction Questionnaire, a validated proprietary questionnaire developed according to FDA guidelines for PRO measures, which assesses treatment satisfaction, appearance, and emotional impact as perceived by patients.
“Regardless of age or gender, most patients contemplating facial aesthetic treatments desire refreshed, natural- looking results, and fear of looking unnatural or a ‘frozen’ look is a common barrier for many,” said Steven Dayan, MD, founder of Denova Research and study author.
“Self-perceived patient satisfaction, both in physical appearance and emotional wellbeing, is paramount
in aesthetics medicine and it is vital physicians understand how patients perceive themselves after treatment to truly address patient concerns and help fulfil their expectations.”
“Assessing patient-reported outcomes for toxin treatments is an important advancement in supporting physicians with reliable data and education to help ensure patients achieve their expected and desired results,” said John Maltman, vice president, global aesthetics medical affairs, AbbVie. “The study supports that patient satisfaction and a desired natural look that helps improve the appearance of upper facial lines can be achieved with proven facial aesthetic neuromodulator treatment.”
